Compare Stocks: VTGN, IZTC, MREO, and GOSS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$0.18 +3.3%	$0.17	$0.11 ▼ $3.87	$42.48M	2	18.48 million shs	4.91 million shs
IZTC Invizyne Technologies	$6.85 +0.7%	$6.32	$8.50 ▼ $23.00	$42.83M	N/A	37,647 shs	1,306 shs
MREO Mereo BioPharma Group	$0.25 +1.2%	$0.30	$0.20 ▼ $2.37	$40.40M	0.32	5.73 million shs	654,741 shs
VTGN VistaGen Therapeutics	$0.25 +0.9%	$0.25	$0.20 ▼ $5.14	$10.92M	0.39	2.05 million shs	178,265 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	0.00%	+3.12%	-1.52%	+9.56%	-94.04%
IZTC Invizyne Technologies	0.00%	-4.43%	+34.18%	-20.53%	-42.73%
MREO Mereo BioPharma Group	0.00%	-6.30%	-15.63%	-18.22%	-85.88%
VTGN VistaGen Therapeutics	0.00%	-4.78%	-15.58%	-54.85%	-93.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$0.18 +3.3%	$0.17	$0.11 ▼ $3.87	$42.48M	2	18.48 million shs	4.91 million shs
IZTC Invizyne Technologies	$6.85 +0.7%	$6.32	$8.50 ▼ $23.00	$42.83M	N/A	37,647 shs	1,306 shs
MREO Mereo BioPharma Group	$0.25 +1.2%	$0.30	$0.20 ▼ $2.37	$40.40M	0.32	5.73 million shs	654,741 shs
VTGN VistaGen Therapeutics	$0.25 +0.9%	$0.25	$0.20 ▼ $5.14	$10.92M	0.39	2.05 million shs	178,265 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	0.00%	+3.12%	-1.52%	+9.56%	-94.04%
IZTC Invizyne Technologies	0.00%	-4.43%	+34.18%	-20.53%	-42.73%
MREO Mereo BioPharma Group	0.00%	-6.30%	-15.63%	-18.22%	-85.88%
VTGN VistaGen Therapeutics	0.00%	-4.78%	-15.58%	-54.85%	-93.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOSS Gossamer Bio	2.22	Hold	$3.20	1,658.24% Upside
IZTC Invizyne Technologies	0.00	N/A	N/A	N/A
MREO Mereo BioPharma Group	2.13	Hold	$1.67	572.04% Upside
VTGN VistaGen Therapeutics	1.80	Reduce	$0.95	289.34% Upside

Current Analyst Ratings Breakdown

Latest VTGN, IZTC, MREO, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	VTGN VistaGen Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underweight
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/11/2026	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	MREO Mereo BioPharma Group	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1.00
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/2/2026	MREO Mereo BioPharma Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/25/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00 ➝ $2.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOSS Gossamer Bio	$48.47M	0.88	N/A	N/A	($0.53) per share	-0.34
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	$500K	79.21	N/A	N/A	$0.26 per share	0.95
VTGN VistaGen Therapeutics	$1.27M	8.53	N/A	N/A	$0.90 per share	0.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOSS Gossamer Bio	-$170.37M	-$0.70	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	-$41.88M	-$0.04	N/A	N/A	N/A	N/A	-74.82%	-64.28%	11/9/2026 (Estimated)
VTGN VistaGen Therapeutics	-$69.68M	-$1.66	N/A	N/A	N/A	-2,702.64%	-152.59%	-117.45%	11/12/2026 (Estimated)

Latest VTGN, IZTC, MREO, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	VTGN VistaGen Therapeutics	-$0.3650	-$0.30	+$0.0650	-$0.30	$0.50 million	$1.48 million
8/13/2026	Q2 2026	GOSS Gossamer Bio	-$0.1234	-$0.08	+$0.0434	-$0.08	$3.63 million	$9.24 million
8/12/2026	Q2 2026	MREO Mereo BioPharma Group	-$0.01	-$0.01	N/A	-$0.05	$3.50 million	N/A
6/15/2026	Q4 2026	VTGN VistaGen Therapeutics	-$0.3367	-$0.37	-$0.0333	-$0.37	$0.40 million	$0.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOSS Gossamer Bio	N/A	0.53	0.53
IZTC Invizyne Technologies	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	5.88	5.88
VTGN VistaGen Therapeutics	N/A	3.07	3.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOSS Gossamer Bio	81.23%
IZTC Invizyne Technologies	N/A
MREO Mereo BioPharma Group	62.83%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
GOSS Gossamer Bio	3.74%
IZTC Invizyne Technologies	N/A
MREO Mereo BioPharma Group	6.50%
VTGN VistaGen Therapeutics	2.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable
IZTC Invizyne Technologies	29	6.25 million	N/A	N/A
MREO Mereo BioPharma Group	40	159.69 million	149.31 million	Optionable
VTGN VistaGen Therapeutics	40	44.38 million	43.08 million	Optionable

VTGN, IZTC, MREO, and GOSS Headlines

Recent News About These Companies

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Rating of "Reduce" from Analysts

August 29, 2026 | americanbankingnews.com

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

August 14, 2026 | globenewswire.com

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

August 6, 2026 | globenewswire.com

SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics

August 4, 2026 | markets.businessinsider.com

Vistagen Appoints Douglas J. Williamson to its Board of Directors

July 31, 2026 | globenewswire.com

Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)

July 18, 2026 | theglobeandmail.com

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

July 15, 2026 | insidermonkey.com

VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst

July 4, 2026 | theglobeandmail.com

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

June 30, 2026 | seekingalpha.com

Vistagen's anxiety disorder drug misses main goal in late-stage trial, shares plummet

June 30, 2026 | reuters.com

Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth

June 17, 2026 | tipranks.com

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

June 15, 2026 | businesswire.com

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 9, 2026 | businesswire.com

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

June 1, 2026 | prnewswire.com

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 19, 2026 | businesswire.com

Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?

May 19, 2026 | insidermonkey.com

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

May 12, 2026 | businesswire.com

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

May 8, 2026 | businesswire.com

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

April 29, 2026 | globenewswire.com

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop

April 28, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN, IZTC, MREO, and GOSS Company Descriptions

Gossamer Bio NASDAQ:GOSS

$0.18 +0.01 (+3.25%)

As of 01:49 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Invizyne Technologies NASDAQ:IZTC

$6.85 +0.05 (+0.74%)

As of 09/4/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Mereo BioPharma Group NASDAQ:MREO

$0.25 +0.00 (+1.20%)

As of 01:49 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

VistaGen Therapeutics NASDAQ:VTGN

$0.24 +0.00 (+0.91%)

As of 01:48 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTGN, IZTC, MREO, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTGN, IZTC, MREO, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTGN, IZTC, MREO, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN, IZTC, MREO, and GOSS Company Descriptions

Gossamer Bio NASDAQ:GOSS

Invizyne Technologies NASDAQ:IZTC

Mereo BioPharma Group NASDAQ:MREO

VistaGen Therapeutics NASDAQ:VTGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTGN, IZTC, MREO, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTGN, IZTC, MREO, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTGN, IZTC, MREO, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN, IZTC, MREO, and GOSS Company Descriptions

Gossamer Bio NASDAQ:GOSS

Invizyne Technologies NASDAQ:IZTC

Mereo BioPharma Group NASDAQ:MREO

VistaGen Therapeutics NASDAQ:VTGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools